MetaCap

Monopar Therapeutics (MNPR) vs Rezolute (RZLT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Monopar Therapeutics (MNPR) has outperformed Rezolute (RZLT) over the past year, losing 24.6% versus a loss of 60.1%. Over five years, MNPR leads with a +184.5% price change compared with -26.9% for RZLT. Monopar Therapeutics is the larger company by market cap ($467.6 million vs $465.6 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MNPR-24.64%RZLT-60.12%
+41%-25%-92%
Nov 21, 20251 yearNov 20, 2026
MNPR+192.99%RZLT-32.41%
+431%+156%-119%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MNPR versus RZLT key metrics
MetricMNPRRZLT
Share price$69.00$3.92
Market cap$467.60M$465.58M
1-day change-1.84%-6.67%
YTD return+5.67%+66.10%
1-year return-24.64%-60.12%
5-year return+184.54%-26.87%
EPS (TTM)$-2.44$-0.76
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0—
Net income (latest FY)$-13.72M$-77.60M
52-week high$124.82$11.17
52-week low$50.07$1.07
Distance from 52-week high-44.72%-64.89%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+88.65%+175.51%
Average volume151.83K1.66M
Shares outstanding6.78M118.77M
Employees2263
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • MNPR has outperformed RZLT by 35.5 percentage points over the past year.

About Monopar Therapeutics

MNPR stock →

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89.

Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees

About Rezolute

RZLT stock →

Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI.

Health Care · Biotechnology: Pharmaceutical Preparations · 63 employees

MNPR vs RZLT FAQ

Which is bigger, Monopar Therapeutics or Rezolute?

Monopar Therapeutics (MNPR) is larger, with a market capitalization of $467.60M compared with $465.58M for Rezolute (RZLT).

Which stock has performed better over the past year, MNPR or RZLT?

MNPR returned -24.64% over the past 12 months, compared with -60.12% for RZLT (price return, excluding dividends). Past performance does not predict future results.

Are Monopar Therapeutics and Rezolute in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons